Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis

Chul Won Jung, Lee Yung Shih, Zhijian Xiao, Jin Jie, Hsin An Hou, Xin Du, Ming Chung Wang, Seonyang Park, Ki Seong Eom, Kenji Oritani, Shinichiro Okamoto, Tetsuzo Tauchi, Jin Seok Kim, Daobin Zhou, Shigeki Saito, Junmin Li, Hiroshi Handa, Li Jianyong, Kohshi Ohishi, Ming HouWu Depei, Katsuto Takenaka, Ting Liu, Yu Hu, Taro Amagasaki, Kazuo Ito, Prashanth Gopalakrishna, Koichi Akashi

研究成果: Contribution to journalArticle

18 引用 (Scopus)

抜粋

Myelofibrosis is characterized by progressive cytopenias, bone marrow fibrosis, splenomegaly and severe constitutional symptoms. In the phase 3 Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies, ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, provided substantial improvements in splenomegaly, symptoms, quality-of-life measures and overall survival compared with placebo or best available therapy. No assessments of the efficacy and safety of ruxolitinib have been conducted in Asian patients. Here, we describe results from an open-label, single-arm, phase 2 trial evaluating ruxolitinib in Asian patients with myelofibrosis (n = 120). The primary endpoint was met, with 31.7% of patients achieving a ≥ 35% reduction from baseline spleen volume at week 24. As measured by the 7-day Myelofibrosis Symptom Assessment Form v2.0, 49% of patients achieved a ≥ 50% reduction from baseline in total symptom score. Adverse events were consistent with those seen in the COMFORT studies. Ruxolitinib was well tolerated in Asian patients with myelofibrosis and provided substantial reductions in splenomegaly and improvements in symptoms.

元の言語英語
ページ(範囲)2067-2074
ページ数8
ジャーナルLeukemia and Lymphoma
56
発行部数7
DOI
出版物ステータス出版済み - 7 1 2015

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

フィンガープリント Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Jung, C. W., Shih, L. Y., Xiao, Z., Jie, J., Hou, H. A., Du, X., Wang, M. C., Park, S., Eom, K. S., Oritani, K., Okamoto, S., Tauchi, T., Kim, J. S., Zhou, D., Saito, S., Li, J., Handa, H., Jianyong, L., Ohishi, K., ... Akashi, K. (2015). Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. Leukemia and Lymphoma, 56(7), 2067-2074. https://doi.org/10.3109/10428194.2014.969260